Related references
Note: Only part of the references are listed.European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-2019 Update
Marko Babjuk et al.
EUROPEAN UROLOGY (2019)
Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer
Takahiro Nohara et al.
INTERNATIONAL JOURNAL OF UROLOGY (2019)
5-Aminolevulinic acid-induced severe hypotension during transurethral resection of a bladder tumor: a case report
Tomoaki Yatabe et al.
JA CLINICAL REPORTS (2019)
Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review
E. M. Wesselink et al.
BRITISH JOURNAL OF ANAESTHESIA (2018)
Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A multicenter phase III study
Yasushi Nakai et al.
INTERNATIONAL JOURNAL OF UROLOGY (2018)
Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas
Walter Stummer et al.
NEUROSURGERY (2017)
Hexyl Aminolevulinate-Guided Fluorescence Cystoscopy in the Diagnosis and Follow-up of Patients with Non-Muscle-invasive Bladder Cancer: A Critical Review of the Current Literature
Michael Rink et al.
EUROPEAN UROLOGY (2013)
Photodynamic Diagnosis of Non-muscle-invasive Bladder Cancer with Hexaminolevulinate Cystoscopy: A Meta-analysis of Detection and Recurrence Based on Raw Data
Maximilian Burger et al.
EUROPEAN UROLOGY (2013)
Risk factors for developing oral 5-aminolevulenic acid-induced side effects in patients undergoing fluorescence guided resection
Ivan Wong Hin Chung et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2013)
Oral 5-aminolevulinic acid induced Photodynamic Diagnostic Ureterorenoscopy-Does the blood pressure require monitoring?
J. Bondad et al.
PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY (2013)
Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study
Stefan Denzinger et al.
UROLOGY (2007)
Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder
Edwin Hungerhuber et al.
UROLOGY (2007)
Protoporphyrin IX generation from δ-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate cyclase activation
Christopher J. Mingone et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions
D Zaak et al.
CANCER (2002)
Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer
JT Dalton et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial
R Ackroyd et al.
GUT (2000)
Porphyrin biosynthesis in human Barrett's oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid
P. Hinnen et al.
BRITISH JOURNAL OF CANCER (2000)
Intravesical administration of 5-aminolevulinic acid (5-ALA) - Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX
G Popken et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2000)
Share Paper
